Drug Search Results
More Filters [+]

Efinopegdutide

Alternative Names: efinopegdutide, jnj-64565111, jnj64565111, jnj 64565111, mk-6024, mk6024, mk 6024, Efinopeg dutide
Latest Update: 2024-10-26
Latest Update Note: Clinical Trial Update

Product Description

Efinopegdutide is a GLP-1/glucagon receptor dual agonist, which activates both the GLP-1 and glucagon receptors. The safety and efficacy of efinopegdutide has previously been evaluated in multiple Phase 1 and Phase 2 clinical trials, including for the treatment of severely obese individuals with and without type 2 diabetes mellitus. (Sourced from: https://www.merck.com/news/merck-and-hanmi-pharmaceutical-enter-into-licensing-agreement-to-develop-efinopegdutide-an-investigational-once-weekly-therapy-for-nonalcoholic-steatohepatitis-nash/)

Mechanisms of Action: GLP-1 Agonist,GcGr Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Efinopegdutide

Countries in Clinic: Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czech Republic, France, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Mexico, New Zealand, Peru, Poland, Portugal, Puerto Rico, Russia, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 12

Highest Development Phases

Phase 2: Fatty Liver, Alcoholic|Hepatitis|Hepatitis, Alcoholic|Liver Cirrhosis|Liver Diseases, Alcoholic|Non-alcoholic Fatty Liver Disease|Non-alcoholic Steatohepatitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

jRCT2031240217

P2

Not yet recruiting

Hepatitis|Liver Cirrhosis

2026-05-15

MK-6024-017

P2

Unknown Status

Hepatitis

2026-05-15

MK-6024-017

P2

Recruiting

Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Liver Diseases, Alcoholic

2026-05-15

MK-6024-013

P2

Active, not recruiting

Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic

2025-12-22

Recent News Events